Lanton Law Blog — Lanton Law

Lanton Law Presents at New York Bar Association's 2020 Annual Meeting

Lanton Law made a presentation on biosimilars at the New York Bar Association’s 2020 Annual Meeting in NYC.

healthcare, life sciences, biologics, BiosimilarsRon LantonFebruary 3, 2020biosimilars, biologics, New York Bar Association

Pharmacy Times Recaps Lanton Law's NASP Presentation on the FDA Biosimilars Action Plan

During the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo, Ron Lanton III, Esq, reviewed the FDA Biosimilars Action Plan, its implications for the biosimilar marketplace, recent legislation set to influence the biosimilar pathway and drug accessibility, and the future of the biosimilar market.

What Will Happen to Biosimilars in the USMCA Agreement in 2020?

Back in August I started an analysis of how biosimilars will be impacted in the new United States-Mexico-Canada Agreement (USMCA). To refresh, in a follow up on a 2016 campaign promise to renegotiate the North American Free Trade Agreement (NAFTA), the Administration has been engaging Mexico and Canada in an effort to create and ratify the USMCA.